FDA Approves Calquence-Venetoclax Fixed-Duration Regimen
AstraZeneca has secured U.S. approval for a new all-oral, fixed-duration treatment regimen for adults with chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL),…
Read More...
Read More...
